Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

Area of Science:

• Oncology
• Nanotechnology
• Immunotherapy

Background:

• Triple-negative breast cancer (TNBC) has limited treatment options and a worse prognosis.
• PD-1/PD-L1 checkpoint inhibitors show potential but have constrained efficacy in TNBC.
• Nanoparticle (NP) technology offers a novel strategy to improve cancer therapy.

Purpose of the Study:

• To review recent NP strategies for enhancing PD-1/PD-L1 blockade-based combination therapy for TNBC.
• To discuss NP designs that improve tumor immunogenicity and target immunosuppressive elements.
• To explore NPs co-loaded with PD-L1 inhibitors and other agents for synergistic effects.

Main Methods:

• Review of recent investigations on NP strategies in TNBC treatment.
• Analysis of NP designs for enhancing tumor immunogenicity and targeting immunosuppression.
• Examination of NPs co-delivering PD-L1 inhibitors and other therapeutic agents.

Main Results:

• NP strategies can optimize the tumor microenvironment for improved therapeutic outcomes.
• Single or multi-therapeutic NPs can enhance tumor immunogenicity and induce immunogenic cell death.
• Co-loading NPs with PD-L1 inhibitors and other agents maximizes efficacy and minimizes toxicity.

Conclusions:

• NP approaches are a promising strategy to enhance PD-1/PD-L1 checkpoint blockade combination therapy in TNBC.
• Further developmental studies are encouraged to explore the full potential of NP-based TNBC treatments.
• Nanoparticles offer a versatile platform for targeted delivery and synergistic effects in TNBC immunotherapy.